[go: up one dir, main page]

UY31716A1 - Composiciones farmacéuticas que presentan un nivel deseado de biodisponibilidad - Google Patents

Composiciones farmacéuticas que presentan un nivel deseado de biodisponibilidad

Info

Publication number
UY31716A1
UY31716A1 UY031716A UY31716A UY31716A1 UY 31716 A1 UY31716 A1 UY 31716A1 UY 031716 A UY031716 A UY 031716A UY 31716 A UY31716 A UY 31716A UY 31716 A1 UY31716 A1 UY 31716A1
Authority
UY
Uruguay
Prior art keywords
present
pharmaceutical compositions
biodisponibility
desired level
compositions
Prior art date
Application number
UY031716A
Other languages
English (en)
Inventor
Bragwati P Kabra
Carmen Martinez
Nuria Jimenez
Puig Elena Gonzalez
Mridvika Garcia
Francisco Javier Galan
Monica Cuchi
Nuria Carreras Perdiguer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41037889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31716A1 publication Critical patent/UY31716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento se refiere a la provisión de composiciones farmacéuticas. Las composiciones contienen un agente terapéutico y una cantidad relativamente baja de agente tensioactivo para proporcionar una mayor biodisponibilidad del agente terapéutico. Las composiciones son particularmente deseables como composiciones oftálmicas en las que el agente terapéutico es un prostaglandina tal como travoprost y el agente tensioactivo es un aceite vegetal tal como aceite de ricino.
UY031716A 2008-03-17 2009-03-16 Composiciones farmacéuticas que presentan un nivel deseado de biodisponibilidad UY31716A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3711708P 2008-03-17 2008-03-17
US11192008P 2008-11-06 2008-11-06

Publications (1)

Publication Number Publication Date
UY31716A1 true UY31716A1 (es) 2009-08-31

Family

ID=41037889

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031716A UY31716A1 (es) 2008-03-17 2009-03-16 Composiciones farmacéuticas que presentan un nivel deseado de biodisponibilidad

Country Status (24)

Country Link
US (5) US20090234004A1 (es)
EP (4) EP2599475B1 (es)
JP (2) JP5654444B2 (es)
KR (1) KR101586357B1 (es)
CN (2) CN101977588A (es)
AR (1) AR070888A1 (es)
AU (1) AU2009225824B2 (es)
BR (1) BRPI0908717B1 (es)
CA (1) CA2716994C (es)
CL (1) CL2009000624A1 (es)
DE (2) DE202009019087U1 (es)
DK (3) DK3042646T3 (es)
ES (3) ES2542728T3 (es)
HK (1) HK1212605A1 (es)
HU (1) HUE025619T2 (es)
MX (1) MX2010009570A (es)
PL (1) PL2265251T3 (es)
PT (1) PT2265251E (es)
RU (1) RU2503453C2 (es)
SI (1) SI2265251T1 (es)
TW (1) TWI544927B (es)
UY (1) UY31716A1 (es)
WO (1) WO2009117316A2 (es)
ZA (1) ZA201006227B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
DK2420223T3 (da) 2008-03-17 2017-11-06 Novartis Ag Vandige farmaceutiske sammensætninger med borat-polyol-komplekser
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
KR20130094293A (ko) * 2010-07-21 2013-08-23 알콘 리서치, 리미티드 향상된 용해도 특성들을 갖는 약학 조성물
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
HRP20230559T1 (hr) 2012-08-24 2023-09-15 Sun Pharmaceutical Industries Limited Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
ES2838756T3 (es) * 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
EP2937076B1 (en) * 2014-04-25 2019-09-11 Alfred E. Tiefenbacher (GmbH & Co. KG) Eye drops containing prostaglandin and tyloxapol
CA2949954A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
UA124698C2 (uk) * 2014-10-20 2021-11-03 Сентіс Фарма Прайвет Лімітед Офтальмологічний розчин
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
PT3373976T (pt) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Formulações tópicas e suas utilizações
WO2017083410A1 (en) * 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
US20210251893A1 (en) 2020-02-06 2021-08-19 Ocular Therapeutix, Inc. Compositions and Methods for Treating Ocular Diseases
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
TWI819317B (zh) * 2021-06-07 2023-10-21 溫士頓醫藥股份有限公司 含前列腺素衍生物的眼用奈米乳劑組合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711708A (en) 1971-02-25 1973-01-16 Optical Coating Laboratory Inc Rapid scan identifier for use in infrared absorption spectroscopy
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
EP0564510A1 (en) * 1990-12-27 1993-10-13 Allergan, Inc Method and composition for disinfecting contact lenses
US5932572A (en) 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) * 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2211361A1 (en) 1995-03-20 1996-09-26 Unilever Plc Liquid cleansing formulations
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
CA2270349A1 (en) * 1996-11-01 1998-05-14 Jesse A. May Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
GB9624928D0 (en) 1996-11-29 1997-01-15 Lintrend Developments Ni Ltd Fibrous products and their production
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
PT1190718E (pt) 1996-12-13 2006-08-31 Alcon Lab Inc Composicoes oftalmicas contendo aminoalcoois
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
JP2002501533A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 高眼圧症治療のための眼科用組成物
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
DE69922916T2 (de) * 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
US6034043A (en) * 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
CN1243548C (zh) 2000-09-13 2006-03-01 参天制药株式会社 滴眼液
WO2002043482A2 (en) 2000-11-29 2002-06-06 Novartis Ag Aqueous disinfecting systems
JP2002332225A (ja) * 2001-05-09 2002-11-22 Lion Corp 眼科用組成物
DE10222388A1 (de) * 2001-05-22 2003-02-13 Denso Corp Kompressor mit veränderbarer Verdrängung
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
KR20050057251A (ko) * 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602004024427D1 (de) 2003-07-31 2010-01-14 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
JP4453815B2 (ja) * 2003-12-08 2010-04-21 ライオン株式会社 ドライアイ治療剤
JP2005247801A (ja) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd 安定な点眼剤
EP1755732A4 (en) 2004-04-23 2008-01-16 Mystic Pharmaceuticals Inc DISPENSING SYSTEM FOR MEDICINAL PRODUCTS IN SEVERAL SINGLE DOSES
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
AU2007304996B2 (en) 2006-09-28 2013-03-21 Novartis Ag Self-preserved aqueous pharmaceutical compositions
WO2008052037A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080095863A1 (en) 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP7569807B2 (ja) 2019-05-31 2024-10-18 カーステン マニュファクチュアリング コーポレーション ゴルフバッグのための変換可能なストラップアセンブリ

Also Published As

Publication number Publication date
AR070888A1 (es) 2010-05-12
US20120029073A1 (en) 2012-02-02
US20090234013A1 (en) 2009-09-17
US20120245227A1 (en) 2012-09-27
US20090234004A1 (en) 2009-09-17
CN105012964A (zh) 2015-11-04
RU2503453C2 (ru) 2014-01-10
EP3042646B1 (en) 2017-05-10
DE202009019114U1 (de) 2016-08-01
DE202009019087U1 (de) 2016-05-20
US8722735B2 (en) 2014-05-13
ES2635197T3 (es) 2017-10-02
ES2637028T3 (es) 2017-10-10
ZA201006227B (en) 2012-02-29
JP2011514384A (ja) 2011-05-06
TW200940068A (en) 2009-10-01
PL2265251T3 (pl) 2015-10-30
SI2265251T1 (sl) 2015-08-31
WO2009117316A3 (en) 2010-09-10
EP2265251B1 (en) 2015-05-27
US20140243409A1 (en) 2014-08-28
US9144561B2 (en) 2015-09-29
AU2009225824B2 (en) 2014-04-10
CN101977588A (zh) 2011-02-16
RU2010142307A (ru) 2012-04-27
EP2599475A2 (en) 2013-06-05
DK2599475T3 (en) 2017-08-21
KR101586357B1 (ko) 2016-01-18
HK1220378A1 (en) 2017-05-05
DK2265251T3 (en) 2015-06-29
CA2716994C (en) 2013-05-28
EP2265251A2 (en) 2010-12-29
PT2265251E (pt) 2015-09-01
CL2009000624A1 (es) 2010-01-04
HUE025619T2 (en) 2016-04-28
EP2705836A1 (en) 2014-03-12
AU2009225824A1 (en) 2009-09-24
US8754123B2 (en) 2014-06-17
KR20110005801A (ko) 2011-01-19
US8178582B2 (en) 2012-05-15
EP3042646A1 (en) 2016-07-13
WO2009117316A2 (en) 2009-09-24
JP2014012744A (ja) 2014-01-23
BRPI0908717A2 (pt) 2020-12-01
BRPI0908717B1 (pt) 2021-12-21
ES2542728T3 (es) 2015-08-10
EP2599475A3 (en) 2013-08-21
TWI544927B (zh) 2016-08-11
MX2010009570A (es) 2010-09-28
JP5654444B2 (ja) 2015-01-14
HK1212605A1 (zh) 2016-06-17
CA2716994A1 (en) 2009-09-24
DK3042646T3 (en) 2017-08-28
EP2599475B1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
UY31716A1 (es) Composiciones farmacéuticas que presentan un nivel deseado de biodisponibilidad
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
CO6571913A2 (es) Derivados de fumarato de ácido graso y sus usos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
CO6361902A2 (es) Composiciones de organogel y procesos para su producción
AR089274A1 (es) Composicion de grasa
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
MX2014000781A (es) Dosis combinada fija de bimatoprost y brimonidina.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
GT201200024A (es) Formulación subcutánea de anticuerpo anti-her2
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
BR112012033755A2 (pt) composições e métodos antissépticos estáveis
MX2019006881A (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
MX2015000442A (es) Composiciones vacuna.
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
CR20150309A (es) Formulaciones de preservación de tejidos y órganos con incremento de estabilidad y vida propia
BR112012012649A2 (pt) agente indutor de beta-defensina humana, formulação, e, usos de um agente indutor de beta-defensiva humana, e de pelo menos uma gordura ou óleo de um triglicerídeo de ácido graxo essencial ou de um derivado do mesmo.
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
GT200900235A (es) Composiciones farmaceuticas
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
PH12015500793A1 (en) Control agent for plant pest and/or plant disease
MY186572A (en) Use of fatty acid ester for improving the antimicrobial efficacy of an alcoholic disinfectant

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200710